{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Taxol", "query": { "intervention": "Taxol" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 2432, "total_pages": 244, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Taxol&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T18:36:07.503Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01820325", "title": "Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lunch Cancer" ], "interventions": [ { "name": "Buparlisib", "type": "DRUG" }, { "name": "Buparlisib placebo", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 6, "start_date": "2013-09-09", "completion_date": "2014-06-18", "has_results": false, "last_update_posted_date": "2018-10-11", "last_synced_at": "2026-09-03T18:36:07.503Z", "location_count": 2, "location_summary": "Fayetteville, Arkansas • Portland, Oregon", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01820325" }, { "nct_id": "NCT03965689", "title": "Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Lung Non-Small Cell Squamous Carcinoma", "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IIIB Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Lung Non-Squamous Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2020-04-16", "completion_date": "2027-03-20", "has_results": true, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-03T18:36:07.503Z", "location_count": 10, "location_summary": "Los Angeles, California • Newport Beach, California • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03965689" }, { "nct_id": "NCT03085004", "title": "CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cyst", "EUS-FNA" ], "interventions": [ { "name": "Ethanol", "type": "DRUG" }, { "name": "Normal saline", "type": "DRUG" }, { "name": "Paclitaxel + Gemcitabine admixture", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2019-04-12", "completion_date": "2026-02-01", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-09-03T18:36:07.503Z", "location_count": 2, "location_summary": "Indianapolis, Indiana • Hershey, Pennsylvania", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03085004" }, { "nct_id": "NCT00280150", "title": "Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 46, "start_date": "2006-01", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2017-06-19", "last_synced_at": "2026-09-03T18:36:07.503Z", "location_count": 3, "location_summary": "Chapel Hill, North Carolina • Concord, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Concord", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00280150" }, { "nct_id": "NCT05285358", "title": "Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Distal Bile Duct Adenocarcinoma", "Gallbladder Carcinoma", "Intrahepatic Cholangiocarcinoma", "Metastatic Malignant Neoplasm in the Peritoneum", "Stage IV Distal Bile Duct Cancer AJCC v8", "Stage IV Intrahepatic Bile Duct Cancer AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IVB Gallbladder Cancer AJCC v8" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2022-09-19", "completion_date": "2028-10-11", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-09-03T18:36:07.503Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05285358" }, { "nct_id": "NCT01853748", "title": "T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 512, "start_date": "2013-05", "completion_date": "2022-06-15", "has_results": true, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-09-03T18:36:07.503Z", "location_count": 85, "location_summary": "Birmingham, Alabama • San Francisco, California • Hartford, Connecticut + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Meriden", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01853748" }, { "nct_id": "NCT03798626", "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Gastroesophageal Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "Gevokizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Modified FOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 167, "start_date": "2019-05-22", "completion_date": "2025-02-05", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-09-03T18:36:07.503Z", "location_count": 3, "location_summary": "Los Angeles, California • St Louis, Missouri • Nashville, Tennessee", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03798626" }, { "nct_id": "NCT04879368", "title": "RegoNivo vs Standard of Care Chemotherapy in AGOC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastro-Oesophageal Cancer" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Trifluridine/Tipracil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Australasian Gastro-Intestinal Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 462, "start_date": "2021-05-05", "completion_date": "2025-04-30", "has_results": true, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-09-03T18:36:07.503Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Sioux City, Iowa + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sioux City", "state": "Iowa" }, { "city": "Edgewood", "state": "Kentucky" }, { "city": "Rapid City", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04879368" }, { "nct_id": "NCT00037089", "title": "A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients With Metastatic Esophageal Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Neoplasm" ], "interventions": [ { "name": "UFT (Tegafur/Uracil)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Edelman, Martin, M.D.", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-03T18:36:07.503Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00037089" }, { "nct_id": "NCT02041533", "title": "An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage IV or Recurrent Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 541, "start_date": "2014-03-27", "completion_date": "2022-05-27", "has_results": true, "last_update_posted_date": "2023-03-02", "last_synced_at": "2026-09-03T18:36:07.503Z", "location_count": 36, "location_summary": "Mobile, Alabama • Gilbert, Arizona • Tucson, Arizona + 30 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02041533" } ] }